R Deva Nathan, MD
Medical Oncology · Chicago, ILNPI 1700987708
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,870 of the $8,464 with a category attached, or 69.4%. 22 manufacturers reported payments, led by Johnson & Johnson at 44.2% of the total. Reporting peaked in 2019 at $4,407 and has fallen 86.3% since, to $603 in 2024.
Across 61 payments — averaging $138.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- GSK$3K
- Daiichi Sankyo Inc.$401
- Takeda Pharmaceuticals U.S.A., Inc.$374
- AstraZeneca$160
- Jazz Pharmaceuticals Inc.$142
- plus $900 from 16 others
What the payments were for
- Consulting fees$5,87069%
- Speaking & faculty fees$3604%
- Travel & lodging$3404%
- Food & beverage$1,89422%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 10 | $3,737 |
| GSK | 1 | $2,750 |
| Daiichi Sankyo Inc. | 3 | $401 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $374 |
| AstraZeneca | 3 | $160 |
| Jazz Pharmaceuticals Inc. | 2 | $142 |
| Agios Pharmaceuticals, Inc. | 1 | $140 |
| Pfizer | 8 | $135 |
| Puma Biotechnology, Inc. | 1 | $122 |
| Genentech USA, Inc. | 4 | $86 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Merck | 3 | $58 |
| Amgen | 2 | $50 |
| Lilly USA, LLC | 2 | $45 |
| Tersera Therapeutics LLC | 1 | $37 |
| Novartis | 2 | $32 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Beigene USA, Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Adaptive Biotechnologies Corporation | 1 | $20 |
| Dova Pharmaceuticals | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,464 in reported general payments places this provider in the 75th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Chicago
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Jyoti PatelChicago$175K
- Al BensonChicago$163K
- Nisha MohindraChicago$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.